Tag: osé
OSE Immunotherapeutics: positive clinical results against ulcerative rectolitis – 02/22/2023 at 18:13
(AOF) – OSE Immunotherapeutics announces the publication in “The Journal of Immunology” of positive Phase 1 clinical results of OSE-127/S95011, an IL-7 receptor (IL-7R) antagonist, developed in partnership with Servier.…
GTT: OSE Engineering participates in the HyMot consortium
By Alexandra Saintpierre Published on 02/14/2023 at 7:26 p.m. Photo credit © GTT (Boursier.com) — GTT announces…
OSE Immuno: start of a first human trial – 22/12/2022 at 12:11
(CercleFinance.com) – OSE Immuno announced on Thursday that it had treated a first patient with its anti-PD1 monoclonal antibody as part of the start of a phase 1/2 trial devoted…
OSE Immunotherapeutics has activated the second tranche of the EIB loan for 10 ME
(Boursier.com) — OSE Immunotherapeutics received a payment of 10 million euros under the 2nd tranche of the loan granted by the European Investment Bank in February 2021. After the drawdown…
OSE Immunotherapeutics receives a payment of 10 million euros for the 2nd tranche of the loan granted by the European Investment Bank – 2022/12/16 at 6:00 pm
This loan aims to support progress in clinical development programs for OSE Immunotherapeutics’ leading products in therapeutic areas with high medical need. Nantes, December 16, 2022, 6 p.m. – OSE…
OSE Immunotherapeutics presents the latest preclinical efficacy data of its IL-7 receptor antagonist OSE-127 in acute lymphoblastic leukemia at the 2022 ASH Annual Meeting – 12/12/2022 at 07:30
Nantes, France – December 12, 2022, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the latest preclinical data on the use of its IL-7 receptor antagonist (IL-7R)…
la chanteuse ose un pantalon totally transparent
La suite après cette publicité NEWSLETTERS you fun, the news, the bonus plan… what else ? La chanteuse et danseuse Shy’m a posté a photo d’elle dans une tenue très…
OSE Immuno: publication in Science Advances of data on CLEC-1, its new myeloid immune checkpoint
By Hector Chaunu Posted on 11/21/2022 at 8:46 p.m. Photo credit © ChaunuPictures …
OSE Immunotherapeutics announces the publication in Science Advances of data on CLEC-1, its new myeloid immune checkpoint – 2022-11-21 at 18:00
Nantes, France – November 21, 2022, 6:00 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces the publication in the peer-reviewed journal Science Advances of data from a…
OSE Immuno: new communications in sight
By Alexandra Saintpierre Published on 08/11/2022 at 7:12 p.m. (Boursier.com) —…
Ose immuno: Thanks to positive announcements for its cancer drug, OSE Immuno is soaring on the stock market
(BFM Bourse) – The Nantes biotechnology company announced Thursday evening that it had received compassionate access authorizations in three European countries for its potential therapeutic vaccine against non-small cell lung…
Unusual volumes on the stock market today: Ose Immunotherapeutics, McPhy Energy
During this trading session on Friday October 21, 2022, abnormal trading volumes were detected on the French market. Today, it is the Ose Immunotherapeutics share that stands out, with trading…